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Background: The Functional Comorbidity Index (FCI) was recently developed to predict physical function in acute
lung injury patients using comorbidity data. Our objectives were to determine: (1) the inter-rater reliability of the
FCI collected using in-patient discharge summaries (primary objective); and (2) the accuracy and predictive validity
of the FCI collected using hospital discharge summaries and admission records versus complete chart review
(secondary objectives).
Methods: For reliability, we evaluated the FCI’s intraclass correlation coefficient (ICC) among trained research staff
performing data collection for 421 acute lung injury patients enrolled in a prospective cohort study. For validity and
accuracy, we compared the detection of FCI comorbidities across three types of inpatient medical records, and the
association of the respective FCI scores obtained with patients’ SF-36 physical function subscale (PFS) scores at
1-year follow-up.
Results: Inter-rater reliability was near-perfect (ICC 0.91; 95% CI 0.89-0.94). Hospital admission records and discharge
summaries (vs. complete chart review) significantly underestimated the total FCI score. However, using multivariable
linear regression, FCI scores collected using each of the three types of inpatient medical records had similar
associations with PFS, suggesting similar predictive value.
Conclusions: Data collection using in-patient discharge summaries represents a reliable and valid method for
collecting FCI comorbidity information.
Keywords: Comorbidity, Intensive care unit, Reproducibility of results, Respiratory distress syndrome, AdultBackground
Survivors of critical illness have significant impairments
in physical function after hospital discharge [1-4]. How-
ever, there is a complex relationship between survivors’
long-term outcomes and their pre-admission comorbid-
ities, critical illness and ICU management. Adjustment
for patients’ baseline comorbidities is essential to under-
stand the independent contributions of critical illness* Correspondence: efan@mtsinai.on.ca
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reproduction in any medium, provided the orand ICU management to survivors’ long-term outcomes.
This issue may be especially important in the elderly, in
whom many chronic illnesses often coexist [5-7].
Comorbidity information can be obtained from a var-
iety of sources, including medical records, patient self-
report, and large administrative databases. Clinical stud-
ies of hospitalized patients commonly rely on medical
records to measure comorbid diseases [8]. However, re-
view of medical records is time consuming, particularly
if the entire medical record is reviewed during a lengthy
and complex hospitalization, which is common with crit-
ically ill patients. Rather than reviewing the entire med-
ical record, researchers may collect comorbidity data
using two alternative methods: (1) prospective collection
from hospital admission records available at the time of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 The Functional Comorbidity Index [9]
Comorbidity
1 Arthritis (rheumatoid and osteoarthritis)
2 Osteoporosis
3 Asthma
4 Chronic obstructive pulmonary disease (COPD), acute
respiratory distress syndrome (ARDS), or emphysema
5 Angina
6 Congestive heart failure (or heart disease)
7 Heart attack (myocardial infarction)
8 Neurological disease (e.g., multiple sclerosis or
Parkinson’s disease)
9 Stroke or transient ischemic attack (TIA)
10 Peripheral vascular disease
11 Diabetes types I and II
12 Upper gastrointestinal disease (e.g., ulcer, hernia, reflux)
13 Depression
14 Anxiety or panic disorders
15 Visual impairment (e.g., cataracts, glaucoma,
macular degeneration)
16 Hearing impairment (i.e., very hard of hearing, even
with hearing aids)
17 Degenerative disc disease (e.g., back disease,
spinal stenosis, or severe chronic back pain)
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on patients’ hospital discharge summary. The latter op-
tion is particularly attractive because these discharge
summaries are frequently available electronically avoid-
ing the need for review of paper-based medical charts.
For these two data collection methods to be useful for
clinical research, they must introduce minimal bias in
the measurement of comorbidity.
The Functional Comorbidity Index (FCI) was recently
developed to predict physical function based on comor-
bidity data [9] and was validated in critically ill patients
with acute lung injury (ALI) [10]. With the FCI, rela-
tively little is known about its inter-rater reliability, and
the validity of these 3 different methods of data collec-
tion (e.g., prospective collection from admission records
versus retrospective collection from discharge summary
versus complete medical chart review). Consequently,
using a cohort of critically ill patients with ALI, our
objectives were to: (1) determine the inter-rater reliabil-
ity of the FCI collected using hospital discharge sum-
mary records; and (2) compare the accuracy and
predictive validity of two abbreviated data collection
methods (i.e., retrospective collection from hospital dis-
charge summaries and prospective collection from hos-
pital admission records) with complete medical record
review (gold standard) on the FCI.18 Obesity and/or body mass index (BMI) > 30Methods
Data sources
Data for this research was obtained from the Improving
Care of Acute Lung Injury Patients (ICAP) study [11].
The ICAP study is a multi-site prospective cohort study
which evaluates long-term outcomes of ALI survivors.
The ICAP study was approved by the Institutional Re-
view Board of the Johns Hopkins University and all par-
ticipating study sites.The functional comorbidity index (FCI)
The FCI is a sum of 18 self-reported comorbid condi-
tions with a score of 0 to 18 (Table 1) [9]. Obesity (i.e.,
BMI > 30) was calculated using height and weight infor-
mation abstracted from the medical chart and was not
assessed directly by any data collection method, leaving
17 comorbid conditions for evaluation in this study. A
higher FCI score indicates greater comorbidity and is
associated with impairment in physical function 1 year
later, as measured by the Medical Outcomes Study
Short-Form 36 (SF-36) Physical Function subscale (PFS)
[12]. The SF-36 is a validated, 36-item generic health-
related quality of life instrument. The PFS of the SF-36
instrument consists of 10 items which assess self-
reported ability with walking, climbing stairs, lifting,
bathing and dressing.Inter-rater reliability of retrospective data collection for FCI
Our primary objective was evaluating the inter-rater reli-
ability of the FCI based on the results of two reviewers
(EF and JMG) who performed independent data collec-
tion from hospital discharge summaries on a conveni-
ence sample of the first 421 patients in the ICAP study
cohort. To evaluate the generalizability of this inter-rater
reliability finding, three additional independent research
assistants similarly performed data collection from hos-
pital discharge summaries on a 30 patient convenience
subset of this sample. Comorbidities were defined as any
distinct patient diagnosis that existed prior to the index
hospitalization for ALI.
Accuracy and predictive validity of prospective and
retrospective data collection for FCI
We calculated the accuracy of FCI’s data collection for
the individual comorbidities and the total FCI score
based on comparison of (1) prospective data collection
from the hospital admission records, and (2) retrospect-
ive collection from hospital discharge summaries versus
complete medical chart review (gold standard) per-
formed by a single data abstractor (EF).
We compared the predictive validity of the total FCI
score, obtained by each of the three data collection
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score and SF-36 PFS score at 1 year. To contrast with
these findings regarding the FCI, we also evaluated the
predictive validity of the Charlson Comorbidity Index
(CCI) [13] and the chronic health points comorbidity
measure of the Acute Physiology and Chronic Health
Evaluation (APACHE) II score [14] for SF-36 PFS score at
1 year.
Power and sample size considerations
Using the method of Walter et al. [15], an analysis of
inter-rater reliability, completed by two reviewers for
421 patients, had >99% power for a target reliability of
0.90, exceeding a minimum reliability (i.e., minimally ac-
ceptable level of reliability) of 0.80 with 1-sided α= 0.05.
For comparisons of inter-rater reliability among all five
reviewers, a sample size of 28 patients was required for
80% power for an obtained reliability of 0.90, exceeding a
minimum reliability of 0.80 with 1-sided α= 0.05. Hence,
for the secondary objective, 30 charts (randomly selected
from patients enrolled in the ICAP study at the Johns
Hopkins Hospital study site) were reviewed by the three
additional independent reviewers, as previously described,
to ensure at least 80% power for all comparisons.
In comparing prospective and retrospective data col-
lection versus complete chart review (gold standard), a
sample size of 59 patients was calculated to detect a 1.5-
unit difference in FCI score, with 95% power and a 2-
sided α= 0.05 (assuming a standard deviation in FCI
score of 1.7 [10]). There is currently no information on a
minimum important difference (MID) for the FCI score.
Therefore, we extrapolated the estimated MID for FCI
from its relationship with the SF-36 PFS. Assuming a
standard deviation of 30 [4,16] and an estimated MID of
10 for the SF-36 PFS [17], the MID for PFS corresponds
to 0.33 standard deviation units. Using the standardized
regression coefficient (−0.361) for the association of FCI
and SF-36 PFS [16], a 1.5-unit difference in FCI score
corresponds to a MID in the SF-36 PFS.
Statistical methods
Descriptive statistics are reported as medians (interquar-
tile range [IQR]) or proportions, and compared using
the Wilcoxon signed-rank test or McNemar’s test,
respectively.
Inter-rater reliability between data collectors was eval-
uated using an intraclass correlation coefficient (ICC)
with 95% confidence intervals (CI) for each FCI individ-
ual comorbidity and for the total FCI score. Using the
nomenclature of Shrout and Fleiss [18], an ICC (2,1) was
calculated to provide a measure of inter-rater reliability
that could be generalized beyond the study. The primary
comparison was between the 2 reviewers who reviewed
the first 421 patients in the ICAP study cohort. For thesecondary objective, we compared all 5 reviewers using
the smaller patient subset. In addition to reporting ICC
quantitatively, the level of agreement from ICC was
reported qualitatively according to the classification sys-
tem of Landis and Koch [19].
For the accuracy analysis (n = 59), the prevalences of
individual FCI comorbidities for each of the two data
collection methods were reported as proportions and
separately compared with the gold standard (complete
chart review) using McNemar’s test. Sensitivity, specifi-
city, and positive/negative predictive values using each
of the hospital admission records and discharge sum-
maries versus the gold standard was determined for the
individual FCI comorbidities.
For predictive validity, the association between FCI
score calculated using each of the three different data
collection methods and the SF-36 PFS score at 1 year
after ALI was determined using ordinary least-squares
linear regression with and without adjustment for age
and gender. For this analysis, we used a 47-patient sub-
set of the original 59 patients sample size with complete
chart review who survived and completed the SF-36 at
1 year. Marked discrepancies in these bivariate and mul-
tivariable associations from the linear regression models
were detected by visual inspection of the overlap of their
95% confidence intervals [20]. The amount of variance
explained in SF-36 PFS score at 1 year, as measured by
R2 for the multivariable model, was compared between
the three different data collection methods. We also
evaluated the amount of variance explained in SF-36
PFS score at 1 year with models using CCI and chronic
health points comorbidity measure of the APACHE II
score instead of FCI.
All statistical analyses were performed using STATA
statistical software version 11.2 (Stata Corporation, Col-
lege Station, TX). A two-sided p-value <0.05 was used to
indicate statistical significance.
Results
Characteristics of study patients
The median age (IQR) for the cohort (n = 421) was 52
(42–63) years and 44% were female. Median (IQR) sever-
ity of illness at ICU admission, as measured by APACHE
II score, was 26 (20–33). Median (IQR) Charlson and
Functional Comorbidity indices, using data from hospital
admission records, was 2 (1–4) and 1 (0–2), respectively.
The median (IQR) SF-36 PFS score at 12 months in the
146 patients who survived (out of a possible 156 patients
who were available for follow-up at 12 months) and had
this assessment done was 55 (25–80).
Inter-rater reliability of hospital discharge summary for FCI
The inter-rater reliability of the FCI score obtained using
hospital discharge summaries (n = 421) between the two
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(95% CI 0.89-0.94). Using a subset of FCI scores (n = 30)
obtained using hospital discharge summaries by all 5
data collectors, inter-rater reliability remained “substan-
tial”, with ICC (95% CI) for all five data collectors, two
original reviewers, and three research assistants: 0.78
(0.66-0.87), 0.89 (0.80-0.95), and 0.71 (0.54-0.84),
respectively.FCI individual comorbidities and total score by data
collection method
The prevalences of individual FCI comorbidities ob-
tained by prospective collection from hospital admission
records and retrospective collection from hospital dis-
charge summaries, compared to complete chart review
(gold standard) are presented in Table 2. As compared
to the gold standard, review of hospital admission
records detected 8 of the 17 FCI comorbidities signifi-
cantly less frequently: arthritis; asthma; COPD, emphy-
sema, or ARDS; congestive heart failure (or heart disease);
neurological disease; upper GI disease; depression; and
anxiety. Moreover, the median (IQR) FCI score calculated
from the hospital admission records was significantlyTable 2 Prevalence of Individual FCI Comorbidities by Data C
FCI Comorbidity, n (%) Gold Standard
Chart
Abstraction
Arthritis (rheumatoid and osteoarthritis) 5 (8)
Osteoporosis 0 (0)
Asthma 7 (12)
COPD, emphysema, or ARDS 7 (12)
Angina 1 (2)
Congestive heart failure (or heart disease) 10 (17)
Myocardial infarction 2 (3)
Neurological disease (e.g., MS or Parkinson’s) 6 (10)
Stroke or TIA 4 (7)
Peripheral vascular disease 4 (7)
Diabetes type I or II 10 (17)
Upper GI disease (e.g., ulcer, hernia, reflux) 23 (39)
Depression 15 (25)
Anxiety or panic disorders 6 (10)
Visual impairment (e.g., cataracts, glaucoma) 0 (0)
Hearing impairment (e.g., hard of hearing with
aids)
0 (0)
Degenerative disc disease (e.g., spinal stenosis) 3 (5)
FCI Score, median (IQR)*** 2 (1–3)
Abbreviations: ARDS, acute respiratory distress syndrome; COPD, chronic obstructive
ischemic attack.
* p-value comparing prospective data collection to chart abstraction, using McNem
** p-value comparing retrospective data collection to chart abstraction, using McNe
*** For the FCI score, comparison made using Wilcoxon signed-rank test.lower than that obtained from the gold standard com-
plete chart review (1 [0–1] vs. 2 [1–3], p < 0.01).
There were no statistically significant differences in
the prevalences of individual FCI comorbidities obtained
by the retrospective collection from hospital discharge
summaries compared to the gold standard. However, the
median (IQR) FCI score calculated from hospital dis-
charge summaries was significantly lower than from the
gold standard (1 [1–2] vs. 2 [1–3], p < 0.01).
As compared to retrospective collection from discharge
summaries, the prospective collection from hospital ad-
mission records detected 11 of 17 comorbidities signifi-
cantly less frequently (Table 3). Myocardial infarction
was the only comorbidity detected significantly more fre-
quently from hospital admission records. The median
(IQR) FCI score calculated from hospital admission
records was significantly lower than that obtained from
the discharge summaries (1 [0–2] vs. 2 [1–3], p < 0.01).
Accuracy of using hospital admission records and
discharge summaries for FCI
The sensitivity, specificity, positive and negative pre-
dictive values for detecting each of the individual FCI








1 (3) 0.05 3 (5) 0.41
0 (0) n/a 1 (2) 0.32
2 (3) 0.03 6 (10) 0.32
0 (0) <0.01 5 (8) 0.32
0 (0) 0.32 0 (0) 0.32
5 (8) 0.05 8 (14) 0.16
2 (3) 1.00 1 (2) 0.32
0 (0) 0.01 8 (14) 0.16
5 (8) 0.32 4 (7) 1.00
1 (3) 0.08 3 (5) 0.32
9 (15) 0.56 10 (17) 1.00
4 (7) <0.01 24 (41) 0.71
3 (5) <0.01 11 (19) 0.16
0 (0) 0.01 6 (10) 1.00
0 (0) 1.00 1 (2) 0.32
0 (0) n/a 0 (0) n/a
0 (0) 0.08 2 (3) 0.32
1 (0–1) <0.01 1 (1–2) <0.01
pulmonary disease; GI, gastrointestinal; MS, multiple sclerosis; TIA, transient
ar’s test.
mar’s test.
Table 3 Prevalence of Individual FCI Comorbidities by
Data Collection Method (n= 421)









4 (1) 23 (5) <0.01
Osteoporosis 4 (1) 10 (2) 0.03
Asthma 16 (4) 28 (7) <0.01
COPD, emphysema, or
ARDS
21 (5) 56 (13) <0.01
Angina 1 (1) 1 (1) 1.00
Congestive heart failure
(or heart disease)
80 (19) 84 (20) 0.07
Myocardial infarction 24 (6) 13 (3) 0.03
Neurological disease
(e.g., MS or Parkinson’s)
7 (2) 55 (13) <0.01
Stroke or TIA 34 (8) 25 (6) 0.32
Peripheral vascular disease 13 (3) 25 (6) <0.01
Diabetes type I or II 105 (25) 81 (19) 0.74
Upper GI disease (e.g., ulcer,
hernia, reflux)
26 (6) 77 (18) <0.01
Depression 39 (9) 62 (15) <0.01
Anxiety or panic disorders 7 (2) 22 (5) <0.01
Visual impairment (e.g.,
cataracts, glaucoma)
2 (1) 9 (2) <0.01
Hearing impairment (e.g.,
hard of hearing with aids)
1 (1) 1 (1) 0.32
Degenerative disc disease
(e.g., spinal stenosis)
8 (2) 14 (3) 0.01
FCI Score, median (IQR)** 1 (0–2) 2 (1–3) <0.01
Abbreviations: ARDS, acute respiratory distress syndrome; COPD, chronic
obstructive pulmonary disease; GI, gastrointestinal; MS, multiple sclerosis; TIA,
transient ischemic attack.
* Comparison made using McNemar’s test.
** For the FCI score, comparison made using Wilcoxon signed-rank test.
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Specifically, discharge summaries were more sensitive
than the hospital admission records in detecting 9 of 17
comorbidities, including chronic respiratory (e.g., asthma,
COPD), neurological, and psychiatric (e.g., depression,
anxiety) disorders.
Predictive validity of the FCI score and SF-36 PFS at
1 year
The bivariate and multivariable linear regression results
evaluating the association between the FCI score ob-
tained from the three different methods of data collec-
tion and the SF-36 PFS score at 1 year are presented in
Table 5. FCI scores calculated from retrospective data
collection using discharge summaries explained slightly
more variance in SF-36 PFS scores at 1 year than either
prospective data collection or complete chart reviewdata, with R2 for the multivariable model of 0.20, 0.18,
and 0.17, respectively.
Multivariate models, adjusted for age and gender,
using the CCI or the chronic health points comorbidity
measure from the APACHE II score explained less vari-
ance in SF-36 PFS scores at 1 year than the FCI score
from hospital discharge summaries, with R2 for the mul-
tivariate model of 0.17 and 0.16, respectively.
Discussion
In our study of 421 acute lung injury patients, we found
substantial inter-rater reliability for FCI across trained
data collectors. A number of comorbidities were under-
detected by the prospectively collecting data using hos-
pital admission records versus a complete chart review.
There were no significant differences in the prevalence
of comorbidities detected retrospectively using discharge
summaries versus complete chart review. Both the pro-
spective and retrospective data collection methods sig-
nificantly underestimated the overall FCI score
compared to the gold standard method. Using multivari-
able regression, adjusting for age and gender, FCI scores
obtained from discharge summaries explained more
variance in SF-36 PFS score at 1 year than FCI score
obtained from hospital admission records or complete
chart review, but all three methods had similar magni-
tudes of association with PFS, suggesting comparative
predictive value. Moreover, FCI scores explained more
variance in SF-36 PFS at 1 year than the Charlson
comorbidity index or the chronic health points of the
APACHE II score at ICU admission.
Adjustment for patients’ baseline comorbidities is es-
sential to understand the independent contributions of
various exposures or therapies to long-term physical
function and outcomes in clinical research. To the best
of our knowledge, this study is the first to evaluate inter-
rater reliability of FCI. Furthermore, despite both hos-
pital admission records and discharge summaries under-
estimating the FCI score (as compared to the gold
standard of complete chart abstraction), all three meth-
ods demonstrated similar associations with the SF-36
PFS at 1 year, suggesting comparative predictive value
for this outcome. Given that the time and effort required
to collect comorbidity information from a discharge
summary is much more efficient than complete chart re-
view, the use of retrospective data collection from hos-
pital discharge summaries is a reliable and valid option
for clinical research that requires comorbidity informa-
tion for predicting SF-36 PFS at 1 year.
Ideally, the comorbidity information obtained from a
variety of patient documentation sources should be simi-
lar, although there are likely important reasons why dif-
ferent data acquisition methods may vary in detection of
individual comorbidities. Specifically in our study, due to
Table 4 Accuracy of Individual FCI Comorbidities by Data Collection Method Compared to Complete Chart Review
(n =59)
FCI Comorbidity Prospective: Retrospective:
Admission Records Discharge Summaries
Sn Sp PPV NPV Sn Sp PPV NPV
Arthritis (rheumatoid and osteoarthritis) 14% 88% 25% 78% 14% 8% 4% 25%
Osteoporosis n/a n/a n/a n/a 0% 23% 0% 75%
Asthma 22% 52% 13% 68% 67% 24% 21% 70%
COPD, emphysema, or ARDS 0% 67% 0% 84% 63% 22% 9% 82%
Angina 0% 50% 0% 50% 0% 50% 0% 50%
Congestive heart failure (or heart disease) 50% 19% 4% 86% 67% 26% 9% 88%
Myocardial infarction 50% 21% 4% 86% 50% 59% 8% 94%
Neurological disease (e.g., MS or Parkinson’s) 0% 89% 0% 91% 100% 23% 11% 100%
Stroke or TIA 100% 17% 15% 100% 80% 40% 16% 93%
Peripheral vascular disease 25% 63% 8% 87% 75% 31% 12% 91%
Diabetes type I or II 50% 27% 7% 83% 50% 40% 9% 88%
Upper GI disease (e.g., ulcer, hernia, reflux) 8% 75% 8% 75% 80% 39% 26% 88%
Depression 17% 53% 8% 74% 56% 33% 16% 76%
Anxiety or panic disorders 0% 74% 0% 77% 67% 30% 17% 80%
Visual impairment (e.g., cataracts, glaucoma) n/a* n/a n/a n/a 0% 36% 0% 83%
Hearing impairment (e.g., hard of hearing with aids) n/a n/a n/a n/a n/a n/a n/a n/a
Degenerative disc disease (e.g., spinal stenosis) 0% 60% 0% 71% 60% 45% 21% 82%
Abbreviations: ARDS, acute respiratory distress syndrome; BMI, body mass index; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; MS, multiple
sclerosis; NPV, negative predictive value; PPV, positive predictive value; Sn, sensitivity; Sp, specificity; TIA, transient ischemic attack.
* n/a if there were no instances of this comorbidity to calculate Sn, Sp, PPV, or NPV.
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mitted to ICU may have a more complete history de-
ferred, including a review of comorbidity information
(e.g., arthritis, osteoporosis, depression) unrelated to
the acute illness, as the health care team initially tries to
resuscitate and stabilize the patient. Thus, prospective data
collection using patient records shortly after ICU admis-
sion may underdetect certain comorbidity information.
Conversely, discharge summaries have the opportunity to
codify the comorbidity information documented by a
number of health care providers over the course of an
entire hospital admission, allowing for potentially more
complete or more important comorbidity to be captured.Table 5 Association Between FCI Score and SF-36 PFS at 1 Ye
Bivariate
Coefficient (95% CI)
Prospective (ICAP original) −6.1 (−10.8 to −1.3)
Retrospective (Discharge summary) −6.0 (−9.4 to −2.7)
Chart review (Gold standard) −6.9 (−12.4 to −1.5)
Abbreviations: CI, confidence interval; RR, relative risk; SF-36 PFS, Short Form-36 Phy
* Linear regression analysis with 47 patients that had complete chart review and co
PFS score at 1 year for every 1 unit increase in FCI score. A 1.5-unit difference in FC
1 year.
** Adjusted for age and sex at ICU admission.Given the variability in the sensitivity of detecting vari-
ous classes of comorbidities by data collection method,
the optimal choice for data collection may vary based on
the population studied, the outcome of interest, and
question to be answered. This is important since preva-
lent comorbidities which may go undetected could result
in substantial bias in the FCI score which is not
accounted for [8]. Conversely, prospective data collec-
tion of comorbidity information may be preferred if
study coordinators are already collecting other data from
the medical chart at admission, and the population being
studied is expected to have few pre-existing comorbid





−3.7 (−8.2 to 0.8) 0.17
−4.5 (−7.7 to −1.3) 0.20
−3.4 (−7.3 to 0.5) 0.18
sical Function Subscale.
mpleted SF-36 at 1 year. Reported coefficients represent the change in SF-36
I score corresponds to a minimum important difference in SF-36 PFS score at
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developed with physical function as the primary out-
come. In creating the FCI, the investigators hypothesized
that diagnoses associated physical function would be dif-
ferent than those associated with mortality as used in
the popular CCI [9-13]. Thus, FCI should outperform
indices designed with mortality as the outcome of inter-
est (e.g., CCI) in predicting physical function. Our re-
sults are consistent with a previous study demonstrating
that, comparing FCI to the CCI and Kaplan-Feinstein
index (KFI), the FCI accounted for more variation in the
SF-36 PFS, highlighting the importance of using risk
models designed to predict a specific outcome.
Our study has potential limitations. While we did not
explicitly evaluate the time required to collect comorbid-
ity information by each of the three methods, it was
clear that retrospective data collection using electronic
discharge summaries was much less time consuming
that complete chart review, and more efficient than pro-
spective data collection from admission records, espe-
cially since it could be completed remotely using
computer access to the records. Furthermore, we did
not evaluate whether a hybrid method (e.g., combined
prospective and retrospective data collection) would be
superior to either method alone. However, the goal of
our study was to demonstrate whether a more efficient
method of data collection (i.e., using electronic discharge
summaries as a retrospective form of data collection)
would have acceptable inter-rater reliability and suffi-
cient validity compared to the gold standard (complete
chart review). Indeed, since we did collect comorbidity
data both prospectively and retrospectively, the final
comorbidity dataset for the ICAP parent study included
comorbidities from both methods. Finally, our results
were obtained from a population of ALI patients, and as
such, may not be generalizable to other populations.
However, the FCI has been validated in ALI patients
[10], and given our hypothesis that more detailed and
comprehensive comorbidity information may be col-
lected and documented in the medical record over the
course of an entire hospital admission, our results are
likely to be applicable to other groups of hospitalized
patients.
Conclusions
FCI comorbidity information collected retrospectively
from discharge summaries had excellent inter-rater re-
liability when performed by trained data collectors.
Retrospective data collection using electronic hospital
dis3charge summaries represents a reliable, and valid
method for collecting FCI comorbidity information. With
the increasing availability of electronic hospital discharge
summaries, the use of retrospective data collection for
FCI comorbidity information is an important tool forICU outcomes research, and potentially for clinical re-
search in other areas of health care.
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